Through a grant provided by MSCRF, Propagenix was able to continue their groundbreaking work in biomedical research of animal models.

Propagenix Inc. (“Engineering personalized solutions for epithelial tissue disease”) is a Rockville, MD-based cell therapy platform technology company providing engineered tissue solutions to address clinical needs in replacing a patient’s own dysfunctional or damaged barrier tissues. The company’s technology is based on the ability to massively expand and differentiate tissue-resident epithelial stem cells.  Applications of this platform technology is directed to the meeting the challenge of manufacturing safe, clinical-scale amounts of biologically functional epithelial cells obtained from individual patients. This deliverable is essential for both transplantation of skin, airway, and corneal lining cells as well as in diagnostic applications in oncology and airway disease. The company’s IP is secured with nine issued patents (eight U.S., one Japan) and multiple additional patents forthcoming.

Propagenix’s partners are biopharmaceutical, medical device, life science, and consumer product firms that access company technology via product sales, licensing and collaborative research agreements. The company has attracted over ten major biopharmaceutical and life sciences firms as clients, including therapeutic-focused deals to access Propagenix technology. 

Leadership Overview

Brian A. Pollok, Ph.D., CEO 
Sherry S. Challberg, Ph.D., COO 


Propagenix has two distinct technologies for the massive expansion of normal or diseased primary epithelial cells, Conditional Reprogramming (CR) technology and EpiX™ technology. Both technologies share particular attributes: epithelial progenitor cells become highly proliferative in these growth-promoting conditions, no transfection or transduction of genetic material is involved, genomic integrity is preserved, and propagated epithelial cells readily return to their committed differentiation fate upon removal from CR and EpiX™ media. While both technologies have a generic, platform utility for cell expansion, they do differ in their ability to support growth of certain cell types. This technology can be applied to conditions and procedures such as biopsies, airway injury and diabetes.


For more information, visit